Effectiveness of RSV Vaccines against RSV-Associated Thromboembolic Events

Emerging infectious diseases 2026 Open access

Read full text
Authors: Ryan E. Wiegand, Heng-Ming Sung, Yue Zhang, Andrea J Chavez, Amber Kautz, Josephine Mak, Morgan Najdowski, Yangping Chen, Yenlin Lai, Yixin Jiao, Yoganand Chillarige, Ruth Link-Gelles
+1 more Amanda B Payne
DOI: 10.3201/eid3202.251520
Cited by: 6
References: 12

Abstract

We evaluated effectiveness of respiratory syncytial virus (RSV) vaccines against RSV-associated thromboembolic events among community-dwelling Medicare fee-for-service beneficiaries >65 years of age in the United States enrolled during October 1, 2023-March 30, 2024. RSV vaccines protected against RSV-associated thromboembolic events (effectiveness 79% [95% CI 74%-83%]) in the same season as vaccine receipt.

Fields of Study & Subjects

Respiratory viral infections research Heparin-Induced Thrombocytopenia and Thrombosis COVID-19 Clinical Research Studies

Publication details

Journal / source
Emerging infectious diseases
Publisher
Centers for Disease Control and Prevention (CDC)
Volume
32
Issue
2
Pages
246–249
Publication date
1 February 2026
Language
EN